Search results for "Intravesical instillation"

Orthotopic Mouse Models of Urothelial Cancer

2017

Orthotopic mouse models of urothelial cancer are essential for testing novel therapies and molecular manipulations of cell lines in vivo. These models are either established by orthotopic inoculation of human (xenograft models) or murine tumor cells (syngeneic models) in immunocompromised or immune competent mice. Current techniques rely on inoculation by intravesical instillation or direct injection into the bladder wall. Alternative models include the induction of murine bladder tumors by chemical carcinogens (BBN) or genetic engineering (GEM).

Does the Compliance to Intravesical BCG Differ between Common Clinical Practice and International Multicentric Trials?

2015

<b><i>Introduction:</i></b> The aim of this study was to analyze the reasons for intravesical BCG interruption in clinical practice. BCG for at least one year is advocated as the best regimen to treat high-risk non-muscle invasive bladder cancer (NMIBC). However, almost 50% of patients don't complete it. Toxicity accounts for 10% of dropouts in international trials. <b><i>Materials and Methods:</i></b> Patients with T1HG NMIBC undergoing 1-year BCG were enrolled in this study. BCG was administered for one year. Toxicity and causes of treatment interruption were recorded. <b><i>Results:</i></b> A total of 411 patients we…

The clinical value of PSA increase during intravesical adjuvant therapy for nonmuscle-invasive bladder cancer.

2016

Introduction Prostatic Specific Antigen (PSA), Bacillus Calmette-Guerin (BCG) increase after intravesical BCG has been reported. The need of prostate biopsy in these patients is object of debate. The aim of our study was to evaluate the effect of intravesical therapy on PSA after transurethral resection (TUR) of nonmuscle-invasive bladder cancer (NMIBC). Materials and methods Patients undergoing intravesical chemotherapy or immunotherapy for NMIBC were entered. PSA was measured before TUR, before the first and after the sixth instillation, 30 and 90 days after the last instillation. Patients with PSA ≥4 ng/ml or palpable prostate nodule were excluded. Results Out of 130 patients, 105 were e…

Adriamycin and Daunomycin in the Treatment of Vesical and Prostatic Neoplasias. Preliminary Results

1972

Our preHrninary experience with adriamycin in tumors of the bladder and prostate is of 25 treatments performed in 21 patients. The discrepancy between the numbers of patients and treatments is due to the fact that some patients were again submitted to various therapeutic cycles upon subsequent admissions. The treatments administered to the same patient at different times are considered individually, with regard either to a different schedule and way of administration of the drug, or to the interposition of other therapeutic means in the intervals between treatments. In addition, 13 patients were treated with daunomycin, as shown in Table 1.

A prospective observational study on oral administration of Ellagic Acid and Annona Muricata in patients affected by non-muscle invasive bladder canc…

2021

Introduction: BCG and MMC shortage and Covid-19 pandemic, more recently, limit accessibility to maintenance regimen in intravesical prophylaxis against recurrence of non-muscle invasive bladder cancer (NMIBC). Ellagic acid (EA) and Annona muricata (AM) exert antitumor activity against different human tumours. An observational prospective study on the prophylactic effect of oral administration of EA+AM in patients avoiding maintenance regimen is presented. Materials and methods: Patients affected by NMIBC and not undergoing maintenance after a 6-week course of intravesical prophylaxis with MMC or BCG were entered. Tis and very high-risk tumours were excluded. After informed consent, the pati…

Intravesical instillation of adriamycin in treatment of bladder cancer

1984

Intravesical Treatment of Superficial Urinary Bladder Tumours with Adriamycin

1980

Personal experience resulted in the observation that intravesical Adriamycin (ADM) is effective in some patients with multiple or diffuse papillary bladder tumours. A review of the literature shows that similar results have been obtained elsewhere, especially in Japan and Sweden. The response rate was higher if single doses of at least 50 mg were employed. Intravesical instillations of ADM appear to be valuable also in the treatment of carcinoma in situ and in prophylactic treatment after transurethral resection (TUR) of papillary bladder tumours.